JDJuan Manuel Dominguez-Salgado

Juan Manuel Dominguez-Salgado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juan Manuel Dominguez-Salgado has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Jorge Maldonado-Hernández

    Unidad de Investigación Médica en Nutrición, Unidad Médica de Alta Especialidad (UMAE), Instituto Mexicano del Seguro Social (IMSS), Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Ciudad de México 06720, Mexico

    6 shared publications
  • Judith Villa-Morales

    Unidad de Investigación Médica en Nutrición, Unidad Médica de Alta Especialidad (UMAE), Instituto Mexicano del Seguro Social (IMSS), Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Ciudad de México 06720, Mexico

    6 shared publications
  • Azalia Juárez-Moya

    Departamento Clínico de Hematología, Unidad Médica de Alta Especialidad (UMAE), Instituto Mexicano del Seguro Social (IMSS), Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Ciudad de México 06720, Mexico

    4 shared publications
  • Benito A. Bautista-Martínez

    Departamento Clínico de Hematología, Unidad Médica de Alta Especialidad (UMAE), Instituto Mexicano del Seguro Social (IMSS), Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Ciudad de México 06720, Mexico

    4 shared publications
  • Karina Anastacia Solís-Labastida

    Departamento Clínico de Hematología, Unidad Médica de Alta Especialidad (UMAE), Instituto Mexicano del Seguro Social (IMSS), Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Ciudad de México 06720, Mexico

    4 shared publications
  • Lourdes Barbosa-Cortés

    Unidad de Investigación Médica en Nutrición, Unidad Médica de Alta Especialidad, Hospital de Pediatría "Dr. Silvestre Frenk Freund," Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social, Ciudad de México, México

    4 shared publications

Latest Publications

  • Open Access

    Cinnamon Supplementation Improves Uric Acid Levels in Adolescents with Obesity: Secondary Metabolic Outcomes from a Randomized Controlled Trial

    by Nancy Lucero Martinez-Rodriguez, Jessie Nallely Zurita-Cruz, Israel Parra-Ortega, Jenny Vilchis-Gil, Miguel Angel Villasis-Keever, Juan Manuel Dominguez-Salgado

    Background: Serum uric acid (SUA) has emerged as a relevant cardiometabolic and hepatic risk marker in adolescents with obesity. Cinnamon has shown metabolic benefits in adults; however, its effects on SUA and hepatic markers in pediatric populations remain unclear. This study aimed to evaluate the efficacy of cinnamon supplementation on serum uric acid, hepatic enzymes, and lipid profiles in adolescents with obesity. Methods: This is a secondary analysis of a randomized, double-blind, placebo-controlled clinical trial including 93 adolescents (10–18 years) with obesity (BMI ≥ 95th percentile). Participants received either 3 g/day of Cinnamomum verum or a placebo for 16 weeks, alongside lifestyle intervention. Changes in BMI z-score, SUA, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), and triglycerides were analyzed. Results: The cinnamon group showed a greater reduction in BMI z-score compared to placebo (Δ −0.08 vs. −0.02; p < 0.001). Serum uric acid decreased significantly in the cinnamon group (median change: −0.5 mg/dL [IQR: −1.0 to −0.2]) compared to placebo (−0.1 mg/dL [IQR: −0.4 to 0.2]; p < 0.01). Triglycerides also decreased in the cinnamon group (−18 mg/dL [IQR: −35 to −5]) versus placebo (−5 mg/dL [IQR: −20 to 10]; p < 0.05). Hepatic enzymes (ALT, AST, and GGT) decreased significantly within both groups, without significant differences between groups. In a subgroup of participants with elevated baseline ALT (n = 67), ALT decreased in both groups (placebo: 32.0 to 30.0 U/L, p = 0.004; cinnamon: 33.0 to 26.0 U/L, p = 0.001), with a greater but non-significant reduction in the cinnamon group (Δ −6.0 vs. −2.0 U/L; p = 0.197). Conclusions: Cinnamon supplementation significantly reduced serum uric acid and improved metabolic parameters in adolescents with obesity. These findings suggest that cinnamon may act as an adjunct strategy targeting early cardiometabolic risk markers, particularly uric acid.

  • Open Access

    Unraveling Stage-Specific Metabolites in Human Milk and Their Links to Maternal Physiology: Insights from a Mexican Population

    by Imelda Cecilia Zarzoza-Mendoza, Maricela Rodríguez-Cruz, María Cristina Carmona-Isunza, Hilda Sánchez-Vidal, José Carlos Páez-Franco, Cristian Emmanuel Luna-Guzmán, Maricela Morales-Marzana, Juan Manuel Domínguez-Salgado, Judith Villa-Morales, Lourdes Barbosa-Cortés

    Background/Objective: Human milk is an irreplaceable source of nutrition and is essential for the infant’s growth and development right after birth and for early life stage survival. This study aims to characterize and compare the metabolite profiles of colostrum and transitional and mature milk using an untargeted GC-MS approach. Additionally, it explores potential correlations between the identified metabolites and maternal nutritional factors. Methods: This was a longitudinal, prospective, and observational study. We included human milk samples from 113 Mexican women who practiced exclusive breastfeeding. Partial least squares-discriminant analysis (PLS-DA) was performed to assess differences among lactation stages. Metabolites showing significant variation across lactation stages were further analyzed using Friedman tests with post hoc Wilcoxon tests and Bonferroni correction. Correlations with maternal anthropometric measures were evaluated. Results: Twenty-three metabolites were identified, including amino acids and derivatives, sugars, fatty acids, and energetic metabolites. Alanine and creatinine levels decreased during lactation, while aspartate, serine, and valine levels increased. Rhamnose level was higher in colostrum, whereas decanoic, dodecanoic, and tetradecanoic acid levels increased over time, and that of 11,14-eicosadienoic acid decreased. Lactic acid levels declined across stages. Negative correlations were found between several amino acids and maternal anthropometric variables, while glyceric acid, rhamnose and lactic acid correlated positively. Conclusions: Human milk metabolomic profiles display distinct, stage-specific variations shaped by maternal characteristics, reflecting the dynamic physiological and nutritional demands of the developing infant


  • Open Access

    Unraveling Stage-Specific Metabolites in Human Milk and Their Links to Maternal Physiology: Insights from a Mexican Population

    by Imelda Cecilia Zarzoza-Mendoza, Maricela Rodríguez-Cruz, M. Cristina Carmona-Isunza, Hilda Sánchez-Vidal, José Carlos Páez-Franco, Cristian Emmanuel Luna-Guzman, Maricela Morales-Marzana, Juan Manuel Dominguez-Salgado, Judith Villa-Morales, Lourdes Barbosa-Cortés

    Background/Objective: Human milk is an irreplaceable source of nutrition, is essential for the infant’s growth and development right after birth and for early life stages survival. This study aims to characterize and compare the metabolite profiles of colostrum, transitional, and mature milk using an untargeted GC-MS approach. Additionally, it explores potential correlations between the identified metabolites and maternal nutritional factors. Methods: This was a longitudinal, prospective, and observational study. We included human milk samples from 113 Mexican women who practiced exclusive breastfeeding. Partial least squares-discriminant analysis (PLS-DA) was performed to assess differences among milk types. Metabolites showing significant variation across lactation stages were further analyzed using Friedman tests with post hoc Wilcoxon tests and Bonferroni correction. Correlations with maternal anthropometric were evaluated. Results: Twenty-three metabolites were identified, including amino acids and derivatives, sugars, fatty acids, and energetic metabolites. Alanine and creatinine decreased during lactation, while aspartate, serine, and valine increased. Rhamnose was higher in colostrum, whereas decanoic, dodecanoic, and tetradecanoic acids increased over time, and 11,14-eicosadienoic acid decreased. Lactic acid declined across stages. Positive correlations were found between several amino acids and maternal anthropometric variables, while lactic acid correlated negatively. Conclusions: Human milk metabolomic profiles display distinct, stage-specific variations shaped by maternal characteristics, reflecting the dynamic physiological and nutritional demands of the developing infant.

  • Open Access

    Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation

    by Lourdes Barbosa-Cortés, Sharon B. Morales-Montes, Michelle Maldonado-Alvarado, Jorge A. Martin-Trejo, Salvador Atilano-Miguel, Emmanuel Jiménez-Aguayo, Fabián I. Martínez-Becerril, Víctor M. Cortés-Beltrán, Atzin V. Hernández-Barbosa, Karina A. Solís-Labastida, et al.

    Background/Objective: In patients with acute lymphoblastic leukemia (ALL), it has been demonstrated that the treatment has a negative effect on bone health. The n-3 polyunsaturated fatty acids (LCPUFAs-ω3) may attenuate bone resorption. We evaluated the effects of LCPUFAs-ω3, vitamin D, and calcium supplementation on bone turnover markers and changes in vitamin D concentrations during 6 weeks of supplementation and during 6 weeks of post-intervention follow-up in pediatric patients with ALL. Methods: Thirty-six pediatric patients with ALL were randomly assigned to the ω-3VDCa group (100 mg/kg/d LCPUFAs-ω3 + 4000 IU vitamin D + 1000 mg calcium) or the VDCa group (4000 IU vitamin D + 1000 mg calcium) for 6 weeks. Blood samples were collected to determine 25(OH)D, PTH, ICTP, and TRAP-5b (biomarkers of bone resorption) and osteocalcin (OC, a biomarker of bone production) levels at baseline, 6 weeks, and 12 weeks after supplementation. The 25(OH)D analysis was performed using ultra-high-performance liquid chromatography coupled to a mass spectrometer, and PTH and bone turnover markers were measured by ELISA. Results: The 25(OH)D concentration increased in both groups (ω3VDCa group: 19.4 ng/mL vs. 44.0 ng/mL, p < 0.0001; VDCa group: 15.3 ng/mL vs. 42.8 ng/mL, p = 0.018) and remained significantly higher at 12 weeks. At 12 weeks, ICTP showed lower concentrations in the ω-3VDCa group than in the VDCa group (0.74 ng/mL vs. 1.05 ng/mL, p = 0.024). Conclusions: Combined omega-3 and 4000 IU vitamin D supplementation for 6 weeks had a positive effect on bone health, as indicated by serum ICTP, with no effect on serum 25(OH)D levels over vitamin D supplementation alone.


  • Open Access

    Impact of Omega-3 and Vitamin D Supplementation on Bone Turnover Markers in Children with Leukemia: Follow-Up During and After Supplementation

    by Lourdes Barbosa-Cortés, Sharon B. Morales-Montes, Michelle Maldonado-Alvarado, Jorge A. Martin-Trejo, Salvador Atilano-Miguel, Emmanuel Jiménez-Aguayo, Fabián I. Martínez-Becerril, Víctor M. Cortés-Beltrán, Atzin V. Hernández-Barbosa, Karina A. Solís-Labastida, et al.

    Background/Objective: In patients with acute lymphoblastic leukemia (ALL), it has been demonstrated that the treatment has a negative effect on bone health. The n-3 polyunsaturated fatty acids (LCPUFAs-ω3) may attenuate bone resorption. We evaluated the effects of LCPUFAs-ω3, vitamin D, and calcium supplementation on bone turnover markers and changes in vitamin D concentrations during 6 weeks of supplementation and 6 weeks post-intervention follow-up in pediatric patients with ALL. Methods: Thirty-six pediatric patients with ALL were randomly assigned to the ω3VDCa group (100 mg/kg/d LCPUFAs-ω3+4,000 IU vitamin D+1,000 mg calcium) or the VDCa group (4,000 IU vitamin D+1,000 mg calcium) for 6 weeks. Blood samples were collected to determine vitamin D (25(OH)D), PTH, ICTP and TRAP-5b (biomarkers of bone resorption) and osteocalcin (OC, a biomarker of bone production) levels at baseline, 6 and 12 weeks after supplementation. The vitamin D analysis was performed using ultra-high-performance liquid chromatography coupled to a mass spectrometer, and PTH and bone turnover markers were measured by ELISA. Results: The 25(OH)D concentration increased in both groups (ω3VDCa group: 19.4 ng/mL vs. 44.0 ng/mL, p< 0.0001; VDCa group: 15.3 ng/mL vs. 42.8 ng/mL, p=0.018) and remained significantly higher at 12 weeks. At 12 weeks, ICTP showed lower concentrations in the ω3VDCa group than in the VDCa group (0.74 ng/mL vs. 1.05 ng/mL, p=0.024). Conclusions: Combined omega-3 and 4,000 IU vitamin D supplementation for 6 weeks had a positive effect on bone health, as indicated by serum ICTP, with no effect on serum 25(OH)D levels over vitamin D supplementation alone.

  • Open Access

    Changes in RANKL, OPG, and 25(OH)D Levels in Children with Leukemia from Diagnosis to Remission

    by Salvador Atilano-Miguel, Lourdes Barbosa-Cortés, Rocío Ortiz-Muñiz, Jorge Maldonado-Hernández, Jorge A. Martin-Trejo, Maricela Rodríguez-Cruz, Lourdes Balcázar-Hernández, Karina A. Solís-Labastida, Benito A. Bautista-Martínez, Azalia Juárez-Moya, et al.

    Background: The receptor activator of the nuclear factor-kB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway is a determining pathway in the balance between bone formation and resorption, and disruptions in this complex can affect bone metabolism. Methods: This study analyzes the changes in RANKL, OPG, and 25(OH)D levels; the RANKL/OPG ratio; and other bone turnover markers (BTMs) from diagnosis to complete remission in children with acute lymphoblastic leukemia (ALL). This is a prospective observational cohort study, carried out at the Instituto Mexicano del Seguro Social, Mexico City, including 33 patients (4–17 years) with newly diagnosed B-cell ALL. The patients were treated with the HP09 chemotherapy protocol. Children who had previously been treated with corticosteroids were excluded. A peripheral blood sample at diagnosis and remission was collected to determine the 25(OH)D and BTM concentrations. Results: Increased RANKL (p = 0.001) and osteocalcin (p < 0.001) levels and RANKL/OPG ratio (p = 0.005) were observed at remission, predominantly in the high-risk (HR) relapse and vitamin D deficiency groups. A negative association between RANKL and OPG (r = −0.454, p = 0.008) was observed. Conclusions: we suggest that the RANKL/OPG ratio could serve as a bone remodeling marker in ALL patients.


  • Open Access

    Changes in RANKL, OPG, and 25(OH)D Levels in Children with Leukemia from Diagnosis to Remission

    by Salvador Atilano-Miguel, Lourdes Barbosa-Cortés, Rocío Ortiz-Muñiz, Jorge Maldonado-Hernández, Jorge A Martin-Trejo, Maricela Rodríguez-Cruz, Lourdes Balcázar-Hernández, Karina A Solís-Labastida, Benito A Bautista-Martínez, Azalia Juárez-Moya, et al.

    Background: The receptor activator of the nuclear factor-kB (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway is a determining pathway in the balance between bone formation and resorption; disruptions in this complex can affect bone metabolism. Methods: This study analyzed the changes in RANKL, OPG and 25(OH)D levels, the RANKL/OPG ratio, and other bone turnover markers (BTM) from diagnosis to complete remission in children with acute lym-phoblastic leukemia (ALL). This is a prospective observational cohort study. This study was carried out in the Instituto Mexicano del Seguro Social in Mexico City. Thirty-three patients (4-17 years) with newly diagnosed B-cell ALL were included. The patients were treated with the HP09 chemotherapy protocol. Children who had previously been treated with corticosteroids were excluded. A pe-ripheral blood sample at diagnosis and remission was collected to determine the 25(OH)D and BTM concentrations. Results: Increased RANKL (p=0.001) and osteocalcin (p


  • Open Access

    Obesity and Hyperandrogenemia in Polycystic Ovary Syndrome: Clinical Implications

    by Mardia López-Alarcón, Víctor Saúl Vital-Reyes, Eduardo Almeida-Gutiérrez, Jorge Maldonado-Hernández, Salvador Flores-Chávez, Juan Manuel Domínguez-Salgado, José Vite-Bautista, David Cruz-Martínez, Aly S. Barradas-Vázquez, Ricardo Z’cruz-López

    Polycystic ovary syndrome (PCOS) is often accompanied with metabolic disturbances attributed to androgen excess and obesity, but the contribution of each has not been defined, and the occurrence of metabolic disturbances is usually not investigated. Ninety-nine women with PCOS and forty-one without PCOS were evaluated. The clinical biomarkers of alterations related to glucose (glucose, insulin, and clamp-derived glucose disposal − M), liver (aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyl transferase), and endothelium (arginine, asymmetric dymethylarginine, carotid intima-media thickness, and flow-mediated dilation) metabolism were measured; participants were categorized into four groups according to their obesity (OB) and hyperandrogenemia (HA) status as follows: Healthy (no-HA, lean), HA (HA, lean), OB (no-HA, OB), and HAOB (HA, OB). Metabolic disturbances were very frequent in women with PCOS (≈70%). BMI correlated with all biomarkers, whereas free testosterone (FT) correlated with only glucose- and liver-related indicators. Although insulin sensitivity and liver enzymes were associated with FT, women with obesity showed lower M (coef = 8.56 − 0.080(FT) − 3.71(Ob); p < 0.001) and higher aspartate aminotransferase (coef = 26.27 + 0.532 (FT) + 8.08 (Ob); p = 0.015) than lean women with the same level of FT. Women with obesity showed a higher risk of metabolic disorders than lean women, independent of hyperandrogenemia. Clinicians are compelled to look for metabolic alterations in women with PCOS. Obesity should be treated in all cases, but hyperandrogenemia should also be monitored in those with glucose-or liver-related disturbances.


  • Open Access

    The Contribution of Obesity and Hyperandrogenemia to the Risk of Metabolic Disturbances of Women with Polycystic Ovary Syndrome Defines the Therapeutic Approach. Clinical Implications

    by Mardia López-Alarcón, Víctor Saul Vital-Reyes, Eduardo Almeida-Gutiérrez, Jorge Maldonado-Hernández, Salvador Flores-Chavez, Juan Manuel Dominguez-Salgado, Jose Vite-Bautista, David Cruz-Martinez, Aly S Barradas-Vazquez, Ricardo Z´cruz-Lopez

    Polycystic ovary syndrome (PCOS) usually comes along with metabolic disturbances attributed to androgen excess and obesity, but the contribution of each has not been defined, and the occurrence of metabolic disturbances is frequently not investigated. We evaluated 99 PCOS and 41 non-PCOS women. Clinical biomarkers of glucose-, liver-, and endothelial-related metabolic alterations were measured; participants were categorized into four groups according with obesity (OB) and hyperandrogenemia (HA) statuses: Healthy (no-HA, lean), HA (HA, lean), OB (no-HA, OB), and HAOB (HA, OB). Metabolic disturbances were highly frequent in PCOS women (70%). BMI correlated with all biomarkers, while free testosterone (FT) only with glucose- and hepatic-related indicators. Despite insulin sensitivity and liver enzymes were associated with FT, women with obesity exhibited lower M [coeff = 8.56 – 0.080(FT) –3.71(Ob); p <0.001)] and higher aspartate aminotransferase (coeff = 26.27 + 0.532(FT) + 8.08(Ob); p = 0.015)] than lean at the same level of FT. Women with obesity exhibited greater risk of metabolic disorders than lean, independently of hyperandrogenemia. Clinicians are compelled to search for metabolic alterations in PCOS women; obesity must be handled in all cases, but hyperandrogenemia needs to be managed also in those with glucose- or liver-related disturbances.